Italian Medicines Agency (AIFA)

Storia delle evidenze sull’uso pediatrico dei farmaci antiemetici

F. Marchetti

2019/6 — pag. 365-369

On 2nd May 2019 the Italian Medicines Agency (AIFA) issued an “Informative Note agreed upon with the European Regulatory Authorities” on domperidone entitled Memorandum on recommendations for minimising heart risks and eliminating prescriptions in ...

Cure palliative pediatriche e uso di farmaci off-label

L. De Zen, F. Marchetti, E. Barbi, F. Benini

2019/2 — pag. 97-102

Paediatric palliative care (PPC) aims to ensure the control of symptoms and the best possible quality of life for patients whose underlying disease, characterised by an unstoppable evolution and negative prognosis, no longer responds to specific tr...

Esiti neonatali e criteri di rimborso per il palivizumab

A. Addis, V. Belleudi, F. Trotta, L. Pinnarelli, M. Davoli

2018/10 — pag. 636-640

In 2016 the Italian Medicines Agency (AIFA) decided to limit the coverage of the prophylaxis with palivizumab following the American Academy of Pediatrics guidelines. In 2017 as a consequence of the strong debate that involved scientific societies, p...

Palivizumab nella profilassi stagionale delle infezioni da virus respiratorio sinciziale

Gruppo di Lavoro regionale della Regione Emilia Romagna (a cura di)

2018/10

La prima lista dei farmaci cardiovascolari autorizzati per un uso pediatrico

Working Group Pediatrico dell’AIFA

2010/3 — pag. 172-176

29 off label drugs that are necessary and irreplaceable to treat cardiovascular pathologies in children are legitimized by the paediatric working group of the Italian Medicines Agency (AIFA). Thus, their use is authorized and they can be supplied b...

Vaccini e Regioni Vaccinare i lattanti contro l’influenza? Il number needed to treat (NNT) nella valutazione dell’impatto delle vaccinazioni

2006/8 — pag. 489-491